Fecal Flora Reconstitution for recurrent clostridium difficile infection: Results and methodology

Journal of Clinical Gastroenterology

Volumn 44, Issue 8, 2010, Pages 567-570

  Rohlke, Faith ^a   Surawicz, Christina M ^b   Stollman, Neil ^a  

^a Northern California Gastroenterology Consultants (NCGC)   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; fecal bacteriotherapy; Fecal Flora Reconstitution; stool transplantation

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; DIPHENOXYLATE; IMMODIUM; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; FECAL FLORA RECONSTITUTION; FECES MICROFLORA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; TRANSPLANTATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955985109     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181dadb10     Document Type: Article

References (40)

1. Bartlett JG, Chang TW, Gurwith M, et al. Antibioticassociated pseudomembranous colitis due to toxin-producing Clostridia. New Eng J Med. 1978;298:531-534.
2. Bergogne-Bérézin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents. 2000;16:521-526. Review.
3. Hove H, Tvede M, Brobech Mortensen PB. Antibioticassociated diarrhea, Clostridium difficile, and short-chain fatty acids. Scand J Gastroenterol. 1996;31:688-693.
4. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16:292-307.
5. Rampal P, Schneider D. Les diarrhées de l'antibiothérapie. Hépatol Gastrol. 1994;1:391-397.
6. Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2008;42(suppl 2):S64-S70.
7. McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
8. Warney M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
9. Fekety R. Guidelines for the diagnosis and management of Clostridium-difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997;92:739-759.
10. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, doubleblinded trial. Clin Infect Dis. 1997;24:324-333.
11. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:1027-1034.
12. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20:43-50.
13. Pépin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006;42:758-764.
14. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
15. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848. [Epub 2007 Feb 2].
16. Kokkotou E, Moss AC, Michos A, et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008;52:1121-1126.
17. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49: 640-645.
18. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
19. Borody TJ, Leis S, Pang G, et al. Fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection. UpTo- Date. August 2006;14.3. Available from: UpToDate clinical information service on the web, http://www.utdol.com/utd/ store/index.do. Accessed May 2008.
20. Borody TJFlora Power"-fecal bacteria cure chronic C. difficile diarrhea. Am J Gastroenterol. 2000;95:3028-3029.
21. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38:475-483. Review.
22. Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis. Am Surg. 1981;47:178-183.
23. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854-859.
24. Faust G, Langelier D, Haddad H, et al. Treatment of recurrent pseudomembraneous colitis with stool transplantation: report of six cases. Can J Gastroenterol. 2002;16:A43.
25. Gustafsson A, Lund-Tonnesen S, Berstad A, et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol. 1998;33:721-727.
26. Gustafsson A, Lund-Tonnesen S, Berstad A, et al. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol. 1999;34:580-586.
27. Macconnachie AA, Fox R, Kennedy DR, et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM. 2009;2. [Epub ahead of print].
28. Paterson DL, Irdell J, Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhoea. Med J Aust. 1994;160:232-233.
29. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficileassociated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283-3285.
30. Schwan A, Sjolin S, Trottestam U. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983;2:845.
31. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet. 1989;1:1156-1160.
32. You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148:632-633.
33. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1:164.
34. Borody TJ,Warren EF, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37:42-47.
35. Borody TJ, George L, Andrews PJ, et al. Bowel flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome Med J Aust. 1989;150:604.
36. Andrews PJ, Borody TJ. Putting back the bugs: bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med J Aust. 1993;159:633-634.
37. Andrews PJ, Barnes P, Borody TJ, et al. Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis. Eur J Gastroenterol Hepatol. 1992;4:245-247.
38. Al-Eidan FA, McElnay JC, Scott MG, et al. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther. 2000;25:101-109.
39. Anand A, Bashey B, Mir T, et al. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol. 1994;89:519-523.
40. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.